UCT-MSC Stem Cells for Orthopedic & Pain Management Practices
UCT-MSC Stem Cells for Orthopedic & Pain Management Practices
Stem Nova Network supplies 25M hUCT-MSC stem cells and 3D-cultured exosome biologics wholesale to licensed orthopedic surgeons, pain management physicians, sports medicine practices, and regenerative medicine clinics. Credential verification is required prior to purchase.
Products for Orthopedic & Pain Practices
25M hUCT-MSC Vial — Research-Grade Biologic · Licensed Professional Use Only · Not FDA-Approved
Human umbilical cord tissue–derived mesenchymal stem cells sourced from first-pregnancy Wharton's Jelly donors. Supplied as a research-grade biologic for licensed professional use only. UCT-MSCs are the most extensively referenced cell type in the orthopedic and pain management biologic literature, with published studies examining intra-articular and other administration routes.
- 25 Million live MSCs per vial — 97% post-thaw viability, lot-documented
- CD90: 100% · CD166: 100% — ISCT-defined MSC identity markers, flow cytometry confirmed
- Endotoxin: 0.935 EU/mL · Sterility: Negative · Mycoplasma: Negative at ≤0.02
- Full viral panel: HCV, HIV, HBV, HTLV, CMV, EBV, HHV, HPV, B19 — all Negative
- Sourced from an AATB-accredited, FDA-registered tissue establishment operating under cGTP standards (21 CFR Part 1271) · Lot CoA every order
- Stored LN₂ vapor phase ≤ -140°C · Shipped on dry ice
3DExo+™ Matrix — 60 Billion EVs · 1mL · Topical Cosmetic Biologic
Cell-free exosome biologic derived from 3D bioreactor-cultured UCT-MSCs. Some orthopedic and pain practitioners incorporate topical exosome biologics as a cosmetic adjunct in their practice. For topical cosmetic use only. Not for injection or therapeutic use.
- 60 Billion NTA-verified EVs per vial · 1mL liquid cryopreserved
- 3D bioreactor-cultured — up to 19.4x higher EV yield vs. 2D flat culture
- Xeno-Free · Serum-Free · Endotoxin-tested · Lot-specific CoA
Quality Documentation for Orthopedic Use
Orthopedic and pain applications require the highest documentation standard of any biologic use. Every Stem Nova Network UCT-MSC lot is independently tested and released with a lot-specific Certificate of Analysis covering:
| Parameter | Specification | SNN Lot Result |
|---|---|---|
| Post-Thaw Viability | ≥ 70% (industry standard) | 97% |
| Cell Count | ≥ 2.0 × 10⁷ cells/vial | 2.4 × 10⁷ cells/vial |
| CD90 Expression | ≥ 80% (ISCT standard) | 100% |
| CD166 Expression | ≥ 80% (ISCT standard) | 100% |
| Endotoxin | ≤ 10 EU/mL (USP <85>) | 0.935 EU/mL |
| Sterility | Negative (21 CFR 610.12) | Negative |
| Mycoplasma | Negative · ≤ 0.02 threshold | Confirmed ≤ 0.02 |
| Full Viral Panel (9 markers) | Negative | All Negative |
What to Require from a Biologic Supplier
Post-Thaw Viability ≥ 90% — Not Just ≥ 70%
Industry minimum is 70%. For orthopedic applications where live cell delivery is the intent, viability at point of use matters significantly. Require lot-specific documentation. SNN current lot: 97%.
Flow Cytometry — CD90 and CD166 ≥ 80%
ISCT-defined MSC identity markers confirmed by flow cytometry on the lot being shipped. Required documentation for any orthopedic biologic supplier.
Full Nine-Marker Viral Screening Panel
HCV, HTLV, CMV, EBV, HIV, HBV, HHV, HPV, and B19 — all tested negative and documented on the lot-specific CoA. Non-negotiable for any allogeneic cell product.
Sterility per 21 CFR 610.12 — Lot-Specific
Must be performed on each individual lot — not a blanket product-line approval. Request the test date and result for the specific lot in your order.
AATB-Accredited, FDA-Registered Tissue Establishment
Sourcing from an AATB-accredited, FDA-registered facility operating under cGTP standards (21 CFR Part 1271) provides the strongest available manufacturing quality signal for allogeneic biologic products. These are facility credentials — not product approval.
Practice Types We Supply
Stem Nova Network supplies research-grade UCT-MSC biologics to licensed practitioners operating within their professional scope and applicable state medical board authority.
All practitioners must be licensed in their respective field. Treatment planning, patient selection, and all clinical decisions are individualized and entirely at the discretion of the licensed practitioner. These products have not been approved by the United States Food and Drug Administration.
Apply for Wholesale Access
Lot-specific CoAs, full viral panel documentation, and dedicated support — available to licensed orthopedic and pain practitioners upon credential verification. Most practices approved within 24 hours.
Enroll Your Practice Today → Contact Our Team